AbbVie reports 99% cure rate for pan-genotypic Hep C therapy
AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.
Read More
